Salarius Pharmaceuticals Investor Relations Material

Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company focuses on developing epigenetic-based cancer treatments. Salarius Pharmaceuticals, Inc. is developing a new class of DNA-targeted anticancer agents that enable the suppression of tumor growth by reversing the aberrant epigenetic changes found in cancer cells. These DNA targeted agents are produced in a fully scalable process that allows rapid scale up to meet commercial demands and enable quick entry into clinical trials.